Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 58106-58108 [E7-20203]
Download as PDF
<![CDATA[
58106
Federal Register / Vol. 72, No. 197 / Friday, October 12, 2007 / Notices
VI. Implementation of Adjusted Fee
Schedule
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
A. Application Fees
Food and Drug Administration
The appropriate application fee
established in the new fee schedule
must be paid for any application or
supplement subject to fees under
PDUFA that is received after September
30, 2007. Payment must be made in U.S.
currency by check, bank draft, or U.S.
postal money order payable to the order
of the Food and Drug Administration.
Please include the user fee ID number
on your check. Your payment can be
mailed to: Food and Drug
Administration, P.O. Box 70963,
Charlotte, NC 28272–0963.
If checks are to be sent by a courier
that requests a street address, the
courier can deliver the checks to:
Wachovia Bank, Attn: Food and Drug
Administration Lockbox 70963, 1525
West WT Harris Blvd., rm. NC0810,
Charlotte, NC 28262. (Note: This
Wachovia Bank address is for courier
delivery only.)
Please make sure that the FDA post
office box number (P.O. Box 70963) is
written on the check. The tax
identification number of the Food and
Drug Administration is 53–0196965.
Wire transfer payment may also be
used. The routing and transit number is
021030004 and the account number is
75060099. Please include, as the
reference, the NDA/BLA number and
the user fee ID number.
FDA is in the process of
implementing alternate Web-based
payment methods. For more information
on these payment options and when
they will be available, please visit FDA’s
Web site at https://www.fda.gov, select
the appropriate user fee type, and click
on ‘‘User Fee Cover Sheet.’’
[Docket No. 2007D–0309]
Draft Guidance for Industry and Food
and Drug Administration Staff; Class II
Special Controls Guidance Document:
Electrocardiograph Electrodes;
Availability; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
SUMMARY: The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of October 4, 2007 (72 FR
56771). The document announced the
availability of a draft guidance entitled
‘‘Class II Special Controls Guidance
Document: Electrocardiograph
Electrodes.’’ The document was
published with an incorrect docket
number. This document corrects that
error.
FOR FURTHER INFORMATION CONTACT:
Joyce A. Strong, Office of Policy (HF–
27), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD
20857, 301–827–7010.
In FR Doc.
E7–19578, appearing on page 56771 in
the Federal Register of Thursday,
October 4, 2007, the following
correction is made:
1. On page 56771, in the third
column, in the heading of the
document, ‘‘[Docket No. 2007N–0309]’’
is corrected to read ‘‘[Docket No.
2007D–0309]’’.
SUPPLEMENTARY INFORMATION:
Dated: October 5, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–20183 Filed 10–11–07; 8:45 am]
BILLING CODE 4160–01–S
B. Establishment and Product Fees
jlentini on PROD1PC65 with NOTICES
FDA will issue invoices for
establishment and product fees for FY
2008 under the new fee schedule in
October 2007. Payment will be due 30
days from the date of the invoice. FDA
will issue invoices in November 2008
for any products and establishments
subject to fees for FY 2008 that qualify
for fees after the October 2007 billing.
Dated: October 4, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. 07–5052 Filed 10–9–07; 12:06 pm]
BILLING CODE 4160–01–S
VerDate Aug<31>2005
16:35 Oct 11, 2007
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Notice of Availability of Draft Policy
Documents for Comment
Health Resources and Services
Administration, HHS.
ACTION: Extension of requests for
comments deadline.
AGENCY:
SUMMARY: The Health Resources and
Services Administration published a
notice in the Federal Register of August
29, 2007, requesting comments on draft
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Agency Guidance (Policy Information
Notices (PINS)) to describe the policy
and processes pertaining to requests
from federally-funded health centers to
change the scope of their Federal
project. The PINS, ‘‘Defining Scope of
Project and Policy for Requesting
Changes,’’ ‘‘Changes in Scope Requests:
Policy for Adding a New Target
Population,’’ and ‘‘Specialty Services
and Health Centers’ Scope of Project,’’
are available on the Internet at https://
bphc.hrsa.gov.
Correction: In the Federal Register of
August 29, 2007, FR Doc. E7–17092, on
page 49724, in the first column, under
DATES, the deadline for comments has
been extended to October 19, 2007.
Dated: October 5, 2007.
Dennis P. Williams,
Deputy Administrator.
[FR Doc. E7–20171 Filed 10–11–07; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
E:\FR\FM\12OCN1.SGM
12OCN1
Federal Register / Vol. 72, No. 197 / Friday, October 12, 2007 / Notices
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
Mrs.
Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs,
SAMHSA/CSAP, Room 2–1035, 1 Choke
Cherry Road, Rockville, Maryland
20857; 240–276–2600 (voice), 240–276–
2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (Formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016. (Formerly:
Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150.
Aegis Sciences Corporation, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400. (Formerly: Aegis Analytical
Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little
Rock, AR 72205–7299, 501–202–2783.
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.
jlentini on PROD1PC65 with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
16:35 Oct 11, 2007
Jkt 214001
Diagnostic Services, Inc., dba DSI,
12700 Westlinks Drive, Fort Myers, FL
33913, 239–561–8200/800–735–5416.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
215–674–9310.
Dynacare Kasper Medical
Laboratories,* 10150–102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2,
780–451–3702/800–661–9876.
ElSohly Laboratories, Inc., 5
Industrial Park Drive, Oxford, MS
38655, 662–236–2609.
Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630.
Kroll Laboratory Specialists, Inc.,
1111 Newton St., Gretna, LA 70053,
504–361–8989 / 800–433–3823.
(Formerly: Laboratory Specialists, Inc.)
Kroll Laboratory Specialists, Inc., 450
Southlake Blvd., Richmond, VA 23236,
804–378–9130. (Formerly: Scientific
Testing Laboratories, Inc.; Kroll
Scientific Testing Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986.
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919–
572–6900/800–833–3984. (Formerly:
LabCorp Occupational Testing Services,
Inc., CompuChem Laboratories, Inc.;
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group)
Laboratory Corporation of America
Holdings, 13112 Evening Creek Drive,
Suite 100, San Diego, CA 92128, 858–
668–3710/800–882–7272. (Formerly:
Poisonlab, Inc.)
Laboratory Corporation of America
Holdings, 550 17th Ave., Suite 300,
Seattle, WA 98122, 206–923–7020/800–
898–0180. (Formerly: DrugProof,
Division of Dynacare/Laboratory of
Pathology, LLC; Laboratory of Pathology
of Seattle, Inc.; DrugProof, Division of
Laboratory of Pathology of Seattle, Inc.)
Laboratory Corporation of America
Holdings, 1120 Main Street, Southaven,
MS 38671, 866–827–8042/800–233–
6339. (Formerly: LabCorp Occupational
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
58107
Testing Services, Inc.; MedExpress/
National Laboratory Center)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS 66219,
913–888–3927 / 800–873–8845.
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Marshfield Laboratories, Forensic
Toxicology Laboratory, 1000 North Oak
Ave., Marshfield, WI 54449, 715–389–
3734/800–331–3734.
MAXXAM Analytics Inc.,* 6740
Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905–817–5700.
(Formerly: NOVAMANN (Ontario), Inc.)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244.
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR 97232,
503–413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology Laboratory,
1 Veterans Drive, Minneapolis, MN
55417, 612–725–2088.
National Toxicology Laboratories,
Inc., 1100 California Ave., Bakersfield,
CA 93304, 661–322–4250/800–350–
3515.
One Source Toxicology Laboratory,
Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888–747–3774. (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
Oregon Medical Laboratories, 123
International Way, Springfield, OR
97477, 541–341–8092.
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942. (Formerly: Centinela
Hospital Airport Toxicology Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7.
Phamatech, Inc., 10151 Barnes
Canyon Road, San Diego, CA 92121,
858–643–5555.
Physicians Reference Laboratory,
7800 West 110th St., Overland Park, KS
66210, 913–339–0372/800–821–3627.
Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340,
770–452–1590/800–729–6432.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated, 7600
Tyrone Ave., Van Nuys, CA 91405, 866–
370–6699 818–989–2521. (Formerly:
E:\FR\FM\12OCN1.SGM
12OCN1
jlentini on PROD1PC65 with NOTICES
58108
Federal Register / Vol. 72, No. 197 / Friday, October 12, 2007 / Notices
SmithKline Beecham Clinical
Laboratories)
S.E.D. Medical Laboratories, 5601
Office Blvd., Albuquerque, NM 87109,
505–727–6300 / 800–999–5227.
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend, IN
46601, 574–234–4176 x276.
Southwest Laboratories, 4645 E.
Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602–438–8507 /
800–279–0027.
Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915,
517–364–7400. (Formerly: St. Lawrence
Hospital & Healthcare System)
St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St., Oklahoma
City, OK 73101, 405–272–7052.
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273.
Toxicology Testing Service, Inc., 5426
N.W. 79th Ave., Miami, FL 33166, 305–
593–2260.
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–5235,
301–677–7085.
The following laboratory will be
voluntarily withdrawing from the HHS
National Laboratory Certification
Program on October 12, 2007:
Meriter Laboratories, 36 South Brooks
St., Madison, WI 53715, 608–267–6225.
(Formerly: General Medical
Laboratories)
*The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
VerDate Aug<31>2005
16:35 Oct 11, 2007
Jkt 214001
Register on April 13, 2004 (69 FR
19644). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Elaine Parry,
Acting Director, Office of Program Services,
SAMHSA.
[FR Doc. E7–20203 Filed 10–11–07; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2007–0069]
Committee Name: Homeland Security
Information Network Advisory
Committee; Notice of Federal Advisory
Committee Meeting
Department of Homeland
Security.
ACTION: Committee Management; Notice
of Federal Advisory Committee Meeting.
AGENCY:
SUMMARY: The Homeland Security
Information Network (HSINAC)
Advisory Committee will meet on
October 31, 2007, in Potomac, MD. The
meeting will be open to the public.
DATES: The HSINAC will meet
Wednesday, October 31, 2007, from 9
a.m. to 4:30 p.m. and on Thursday,
November 1, 2007, from 8:30 a.m. to 12
p.m. Please note that the meeting may
close early if the committee has
completed its business.
ADDRESSES: The meeting will be held at
Bolger Center, 9600 Newbridge Drive,
Potomac, MD 20854–4436. Send written
material, comments, and requests to
make oral presentations to Elliott
Langer, Department of Homeland
Security, 245 Murray Lane, SW., Bldg
410, Washington, DC 20528. Written
materials, comments, and requests to
make oral presentations at the meeting
should reach the contact person listed
below by October 20, 2007. Requests to
have a copy of your material distributed
to each member of the committee prior
to the meeting should reach the contact
person at the address below by October
20, 2007. Comments must be identified
by DHS–2007–0069 and may be
submitted by one of the following
methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• E-mail: elliott.langer@dhs.gov.
Include the docket number in the
subject line of the message.
• Fax: 202–282–8191.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
• Mail: Elliott Langer, Department of
Homeland Security, 245 Murray Lane,
SW., Building 410, Washington, DC
20528.
Instructions: All submissions received
must include the words ‘‘Department of
Homeland Security’’ and the docket
number for this action. Comments
received will be posted without
alteration at www.regulations.gov,
including any personal information
provided.
Docket: For access to the docket to
read background documents or
comments received by the Homeland
Security Information Network Advisory
Committee, go to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Elliott Langer, 245 Murray Lane, SW.,
Bldg 410, Washington, DC 20528,
Elliott.langer@dhs.gov, 202–282–8978,
fax 202–282–8191.
Notice of
this meeting is given under the Federal
Advisory Committee Act, 5 U.S.C. App.
(Pub. L. 92–463). The mission of the
HSINAC is to identify issues and
provide independent advice and
recommendations for the improvement
of HSIN to senior leadership of the
Department, in particular the Director of
Operations Coordination. The agenda
for the first meeting will consist of a
briefing on the development of HSIN
and identifying overarching strategic
issues concerning HSIN development as
well as user operational requirements.
In addition, discussions will provide an
opportunity for initial discussion to
identify issues and concerns held by
state, local, tribal and private sector
users.
SUPPLEMENTARY INFORMATION:
Procedural
This meeting is open to the public.
Please note that the meeting may close
early if all business is finished.
Participation in HSINAC deliberations
is limited to committee members,
Department of Homeland Security
officials, and persons invited to attend
the meeting for special presentations.
All visitors to Bolger Center will have
to pre-register to be admitted to the
building. Please provide your name,
telephone number by close of business
on October 20, 2007, to Elliott Langer
(202–282–8978)
(Elliott.langer@dhs.gov).
Information on Services for Individuals
With Disabilities
For information on facilities or
services for individuals with disabilities
or to request special assistance at the
E:\FR\FM\12OCN1.SGM
12OCN1
]]>Agencies
[Federal Register Volume 72, Number 197 (Friday, October 12, 2007)]
[Notices]
[Pages 58106-58108]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-20203]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories Which Meet Minimum Standards To
Engage in Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories currently certified to meet the
standards of Subpart C of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory
Guidelines were first published in the Federal Register on April 11,
1988 (53 FR 11970), and subsequently revised in the Federal Register on
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on
April 13, 2004 (69 FR 19644).
A notice listing all currently certified laboratories is published
in the Federal Register during the first week of each month. If any
laboratory's certification is suspended or revoked, the laboratory will
be omitted from subsequent lists until such time as it is restored to
full certification under the Mandatory Guidelines.
If any laboratory has withdrawn from the HHS National Laboratory
Certification Program (NLCP) during the past month, it will be listed
at the end, and will be omitted from the monthly listing thereafter.
[[Page 58107]]
This notice is also available on the Internet at https://
www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in
accordance with Executive Order 12564 and section 503 of Public Law
100-71. Subpart C of the Mandatory Guidelines, ``Certification of
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets
strict standards that laboratories must meet in order to conduct drug
and specimen validity tests on urine specimens for Federal agencies. To
become certified, an applicant laboratory must undergo three rounds of
performance testing plus an on-site inspection. To maintain that
certification, a laboratory must participate in a quarterly performance
testing program plus undergo periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of
certification are not to be considered as meeting the minimum
requirements described in the HHS Mandatory Guidelines. A laboratory
must have its letter of certification from HHS/SAMHSA (Formerly: HHS/
NIDA) which attests that it has met minimum standards.
In accordance with Subpart C of the Mandatory Guidelines dated
April 13, 2004 (69 FR 19644), the following laboratories meet the
minimum standards to conduct drug and specimen validity tests on urine
specimens:
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016. (Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY
14624, 585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101,
Memphis, TN 38118, 901-794-5770/888-290-1150.
Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210,
615-255-2400. (Formerly: Aegis Analytical Laboratories, Inc.)
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7,
Little Rock, AR 72205-7299, 501-202-2783. (Formerly: Forensic
Toxicology Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802,
800-445-6917.
Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort
Myers, FL 33913, 239-561-8200/800-735-5416.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602,
229-671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA
18974, 215-674-9310.
Dynacare Kasper Medical Laboratories,* 10150-102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702/800-661-9876.
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS
38655, 662-236-2609.
Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT,
Canada N6A 1P4, 519-679-1630.
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA
70053, 504-361-8989 / 800-433-3823. (Formerly: Laboratory Specialists,
Inc.)
Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond,
VA 23236, 804-378-9130. (Formerly: Scientific Testing Laboratories,
Inc.; Kroll Scientific Testing Laboratories, Inc.)
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan,
NJ 08869, 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984. (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 13112 Evening Creek
Drive, Suite 100, San Diego, CA 92128, 858-668-3710/800-882-7272.
(Formerly: Poisonlab, Inc.)
Laboratory Corporation of America Holdings, 550 17th Ave., Suite
300, Seattle, WA 98122, 206-923-7020/800-898-0180. (Formerly:
DrugProof, Division of Dynacare/Laboratory of Pathology, LLC;
Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of
Laboratory of Pathology of Seattle, Inc.)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa,
KS 66219, 913-888-3927 / 800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North
Oak Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734.
MAXXAM Analytics Inc.,* 6740 Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905-817-5700. (Formerly: NOVAMANN (Ontario), Inc.)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN
55112, 651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff,
Pasadena, TX 77504, 888-747-3774. (Formerly: University of Texas
Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology
Laboratory)
Oregon Medical Laboratories, 123 International Way, Springfield, OR
97477, 541-341-8092.
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942. (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509-755-8991/800-541-7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121,
858-643-5555.
Physicians Reference Laboratory, 7800 West 110th St., Overland
Park, KS 66210, 913-339-0372/800-821-3627.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA
30340, 770-452-1590/800-729-6432. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA
19403, 610-631-4600/877-642-2216. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA
91405, 866-370-6699 818-989-2521. (Formerly:
[[Page 58108]]
SmithKline Beecham Clinical Laboratories)
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM
87109, 505-727-6300 / 800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x276.
Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507 / 800-279-0027.
Sparrow Health System, Toxicology Testing Center, St. Lawrence
Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-364-7400. (Formerly:
St. Lawrence Hospital & Healthcare System)
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101, 405-272-7052.
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273.
Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL
33166, 305-593-2260.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson
St., Fort George G. Meade, MD 20755-5235, 301-677-7085.
The following laboratory will be voluntarily withdrawing from the
HHS National Laboratory Certification Program on October 12, 2007:
Meriter Laboratories, 36 South Brooks St., Madison, WI 53715, 608-
267-6225. (Formerly: General Medical Laboratories)
*The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 13, 2004 (69 FR 19644).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Elaine Parry,
Acting Director, Office of Program Services, SAMHSA.
[FR Doc. E7-20203 Filed 10-11-07; 8:45 am]
BILLING CODE 4160-20-P
